

Information Governance

Robert Dolan House 9 Alie Street London E1 8DE

Email elft.foi@nhs.net

Website: https://www.elft.nhs.uk

18 January 2024

Our reference: FOI DA5098

I am responding to your request for information received 6 December 2023 and clarified on 21 December. This has been treated as a request under the Freedom of Information Act 2000.

I am now enclosing a response which is attached to the end of this letter. Please do not hesitate to contact me on the contact details above if you have any further queries.

Yours sincerely,

Information Rights Coordinator

If you are dissatisfied with the Trust's response to your FOIA request then you should contact us and we will arrange for an internal review of this decision.

If you remain dissatisfied with the decision following our response to your complaint, you may write to the Information Commissioner for a decision under Section 50 of the Freedom of Information Act 2000. The Information Commissioner can be contacted at:

Information Commissioner's Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF

Tel: 0303 123 1113 Web: www.ico.org.uk

Please note that the data supplied is not allowed to be re-used and/or published without the explicit consent of East London NHS Foundation Trust. Please contact the signatory to request permission if this is your intention

Interim Chief Executive Officer: Lorraine Sunduza

Chair: Eileen Taylor

Request: This is a freedom of information request under the Freedom of Information

Act 2000. Please provide the following information you have pertaining to

NHS Trust unlicensed medicine expenditure.

Question 1: What is the total value of spend by your NHS Trust on unlicensed medication

(i.e. Special Order, Drug Tariff Special Order, Part VIIID Drug Tariff Special Order) that have a BNF liquid formulation (e.g. liquid, solution, suspension)? Please provide this information on a volume and value basis for the

following years - Apr-20 to Mar-21, Apr-21 to Mar-22, Apr-22 to Mar-23.

(please fill in the tables below).

Note: Value of spend to mean either net ingredient cost or actual cost. Please state which you have used below. Actual cost would be the total cost to NHS commissioners whereas NIC is the cost at list price excluding VAT.

Answer: Please see table below:

Total Value	Total spend / cost on liquid unlicensed products procured			
Туре	Apr-20 to Mar-21	Apr-21 to Mar-22	Apr-22 to Mar-23	
Special Order	Data not available - the pharmacy	Data not available - the pharmacy		
Drug Tariff Special Order	stock system only provides	stock system only provides	£64,198.23	
Part VIIID Drug Tariff Special Order	accessible data for current and	accessible data for current and		
Other Special	previous financial year.	previous financial year.		

Question 2: What is the total volume by your NHS Trust on unlicensed medication (i.e. Special Order, Drug Tariff Special Order, Part VIIID Drug Tariff Special Order) that have a BNF liquid formulation (e.g. liquid, solution, suspension)? Please provide this information on a volume and value basis for the following years - Apr-20 to Mar-21, Apr-21 to Mar-22, Apr-22 to Mar-23.


Clarification - Volume can either refer to total mls or units depending on which is easiest to analyse from a data pov.

Answer: Please see table below:

Total Volume	Total volume of liquid unlicensed products procured			
Туре	Apr-20 to Mar-21	Apr-21 to Mar-22	Apr-20 to Mar-21	
Special Order	Data not available -	Data not available -	248600ml,	
Drug Tariff Special Order	the pharmacy stock system only provides	the pharmacy stock system only provides	total 1577 packs (bottles)	
Part VIIID Drug Tariff Special Order	accessible data for current and previous financial	accessible data for current and previous financial		
Other Special	year.	year.		

Question 3: Do you outsource the manufacturing of liquid unlicensed products?

Answer: Yes.



Chair: Eileen Taylor

Question 4: If no to question 3 (use of outsourcing providers), what proportion of the products that you manufacture in-house are aseptically compounded rather than terminally sterilised?

Answer: Not applicable.

Question 5: If yes to question 3 (use of outsourcing providers), what is the total value of

spend by provider? Please provide this information for the following years -

Apr-20 to Mar-21, Apr-21 to Mar-22, Apr-22 to Mar-23.

(please fill in the tables below).

Note: If more than 10 providers are used, please only detail spend with the

top 10.

Answer: Please see table below:

Outsourcing provider	Total value of liquid specials procured from each provider			
fill in empty rows with provider name, add rows if required)	Apr-20 to Mar-21	Apr-21 to Mar-22	Apr-22 to Mar-23	
Rosemont Pharmaceuticals	Data not available - the pharmacy stock system only provides accessible data for current and previous financial year.	Data not available - the pharmacy stock system only provides accessible data for current and previous financial year.	£64,198.23	